ArticleDiagnostic pathology2014
Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma.
Article in Diagnostic pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Independent Prognosis Prediction of Hepatocellular Carcinoma Using MicroRNA-Based Single and Combined Biomarkers.Canadian journal of gastroenterology & hepatology · 2026Review
- Independent prognostic significance of tissue and circulating microrna biomarkers in hepatocellular carcinoma.Discover oncology · 2025Review
- Small RNA Profiling in an HTLV-1-Infected Patient with Acute Adult T-Cell Leukemia-Lymphoma at Diagnosis and after Maintenance Therapy: A Case Study.International journal of molecular sciences · 2023Article
- miR-106b as an emerging therapeutic target in cancer.Genes & diseases · 2022Review
- Effects of miR‑106b‑3p on cell proliferation and epithelial‑mesenchymal transition, and targeting of ZNRF3 in esophageal squamous cell carcinoma.International journal of molecular medicine · 2019Article
- Prognostic value of miR17-92 family in patients with digestive system cancers: a systematic review and meta-analysis.Cancer management and research · 2019Review
- Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation.Theranostics · 2019Article
- miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC.Oncology letters · 2018Article
- Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma.Oncotarget · 2018Article
- Serum miR-106b upregulation predicts poor prognosis in patients with colorectal cancer.International journal of clinical and experimental pathology · 2018Article
- Article
- HBeAg-induced miR-106b promotes cell growth by targeting the retinoblastoma gene.Scientific reports · 2017Article
- Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes.Oncotarget · 2017Review
- Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.Scientific reports · 2016Review
- MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression.Journal of experimental & clinical cancer research : CR · 2016Article
- MicroRNA-106b is involved in transforming growth factor β1-induced cell migration by targeting disabled homolog 2 in cervical carcinoma.Journal of experimental & clinical cancer research : CR · 2016Article
- Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.World journal of gastroenterology · 2015Review
- MicroRNA-106b promotes colorectal cancer cell migration and invasion by directly targeting DLC1.Journal of experimental & clinical cancer research : CR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-106b (miR-106b) is a member of the miR-106b ~ 25 cluster. It has been reported that miR-106b acts as an oncogene and is upregulated in many human cancers. However, the prognostic value of miR-106b in hepatocellular carcinoma (HCC) remains unclear. The aim of this study was to investigate the clinical significance of miR-106b expression in HCC.
methodsWe determined the expression level of miR-106b in 104 cases of paired HCC and adjacent non-tumor tissues by quantitative real-time PCR (qRT-PCR). The correlation between miR-106b expression and prognosis of HCC was studied by univariate and multivariate analysis. Multivariate analysis of the prognostic factors was performed with Cox proportional hazards model.
resultsMiR-106b expression was significantly upregulated in as high as 76.0% of HCC tissues, compared with their non-tumor counterparts (P < 0.001). High miR-106b expression was significantly associated with large tumor size (P = 0.019) and vascular invasion (P = 0.016). Kaplan-Meier analysis showed that patients with high miR-106b expression had a worse overall survival than patients with low miR-106b expression (log-rank P = 0.004). The multivariate Cox regression analysis indicated that miR-106b expression was an independent prognostic factor for overall survival (HR, 2.002; 95% CI, 1.130-6.977; P = 0.027).
conclusionOur data indicated that miR-106b expression was significantly upregulated in HCC and could serve as a potential unfavorable prognostic biomarker. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_226.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.